Q-omics provides the consensus-scored MSANTD3-TMEFF1 profile across patient tissues and cancer cell-line models. MSANTD3-TMEFF1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MSANTD3-TMEFF1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MSANTD3-TMEFF1 RNA expression shows 17,577 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where MSANTD3-TMEFF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSANTD3-TMEFF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSANTD3-TMEFF1 survival associations across molecular data types. MSANTD3-TMEFF1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSANTD3-TMEFF1 RNA expression–survival associations across cancer types. High MSANTD3-TMEFF1 expression shows unfavorable associations in MESO, CESC, BLCA, LUAD and KIRP, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for MSANTD3-TMEFF1 RNA expression.
This table summarizes MSANTD3-TMEFF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MSANTD3-TMEFF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSANTD3-TMEFF1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, KIRC, LIHC and CHOL. The HNSC box plot shows higher MSANTD3-TMEFF1 RNA expression in tumor versus normal tissue (log2 FC = +0.142, t-test p < 0.001).
This table shows molecular features associated with MSANTD3-TMEFF1 in patient tissues and cancer cell lines. In patient samples, MSANTD3-TMEFF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MSANTD3-TMEFF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
